|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Probiotics may be as effective as 5-ASAs in preventing relapse of quiescent UC.
|
28653751 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Related randomized controlled trials (RCTs) that compared one TCM intervention with another or with 5-ASA (placebo) for mild-to-moderate UC from inceptions to February 2019 will be included.
|
31415431 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simple Urine Test to Evaluate Adherence to Oral 5-ASA in Teenagers With Ulcerative Colitis: Proof of Concept.
|
28169975 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to systematically review the literature and update evidence concerning effects of 5-ASA on the risk of colorectal cancer (CRC) and dysplasia (Dys) in patients with ulcerative colitis (UC) or Crohn's disease (CD).
|
27906680 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The choice of treatment for refractory UC patients who are allergic to 5-ASA is relatively limited.
|
29742710 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The experimental data revealed that the synthesized terpolymeric semi-IPN hydrogel may have useful biomedical applications, especially as a carrier of protein (BSA), or 5-ASA (a therapeutic option for conditions of the colon such as Crohn's Disease and Ulcerative Colitis).
|
30813044 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common treatments at baseline were biologics (75.3%) and immunosuppressants (70.9%) for CD patients and 5-ASA compounds (77.5%) for UC patients.
|
31636478 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results from questionnaire survey showed that majority of physicians would prefer oral 5-ASA with topical 5-ASA therapy for distal UC patients.
|
30659678 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The subjects were 67 patients with UC who were treated with a pH-dependent or time-dependent formulation of 5-ASA between December 2011 and April 2014.
|
30369547 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was a significant decrease of NHE-1 and a significant increase (P < 0.05) of TLR-4, MyD88 and NFkB protein levels in the untreated UC or 5'-ASA plus steroid treated UC patients as compared to the controls.
|
21221801 |
2011 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This prospective study included 121 UC outpatients treated using 5-ASA tablets.
|
30179881 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To design and prepare 5‑ASA‑loaded silicon dioxide nanoparticles (5‑ASA‑SiO2 NPs), a micro‑emulsion method was conducted, and their respective therapeutic effects were validated in a mouse model of UC.
|
28138699 |
2017 |
|
Ulcerative Colitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC.
|
31013494 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing.
|
28453754 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of mesalamine (5-ASA) in the treatment of ulcerative colitis modulates the risk of neoplastic progression. p21 activated kinase 1 (PAK1) mediates 5-ASA activity by orchestrating MAPK signaling, Wnt-β catenin pathway, and cell adhesion; all implicated in the colon carcinogenesis.
|
25569743 |
2015 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to identify predictors of low adherence to oral 5-ASA in Koreans with UC.
|
30901362 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-ASA modifies clinical outcomes among anti-tumor necrosis factor (TNF)-α-treated patients.
|
29925913 |
2018 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care.
|
29073323 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore determined genetic variations of NAT1 in patients with UC and looked for a possible association with the clinical response to 5-ASA.
|
18322880 |
2008 |